Search Job Title Only
News By Subject
News by Disease
News By Date
Get Our FREE
£28M Third Round Enough To Last Until 2007
10/19/2005 5:10:10 PM
Arakis Ltd. raised £29 million (US$52 million) in its third funding round, providing enough money to take the company to 2007 and allowing it to start U.S. and European Phase III trials of AD 923 in cancer breakthrough pain.
With £29 Million
Closes $30 Million Series B Financing
Will A Clinical Trial Database Help Investors?
Gives Up Facility
Expected Call For Advance Registration Of Drug Tests
Drug Makers Take Aim At Counterfeiting
Drug Industry Site Will Show Trials
Corvallis Business Will Be Studying Bioterrorism Threat; NIH Awards $12M
Epoch Biosciences, Inc.
(EBIO) Agree To Merge
UK Animal Experiments On The Increase
comments powered by Disqus.
comments powered by
Arakis Ltd. (Acquired by Sosei Co. Ltd.)
Biotech/Pharma - Finance
Biotech/Pharma - Investor